Hypertension
Conditions
Keywords
Hypertension, carvedilol, bisoprolol, central pulse pressure, pulse pressure amplification, reflection magnitude, LV mass index, LV diastolic function
Brief summary
The purpose of this study is to compare of carvedilol, a vasodilating beta-blocker and bisoprolol, a beta1- selective beta-blocker for reducing the central pulse pressure and thereby left ventricular (LV) mass in never-treated hypertensive patients.
Detailed description
Carvedilol and bisoprolol are established beta-blockers for treating hypertension or chronic heart failure because these beta-blockers have cardio-protective effects. Recent studies have shown that the change in central pulse pressure is more closely associated with the change in cardiac load than the change in brachial pressure during hypertension treatment. Vasodilating beta-blockers may decrease central pulse pressure more than beta1- selective beta-blockers, because vasodilators reduced the magnitude of reflection wave by dilating peripheral muscular arteries. The investigators hypothesized that carvedilol, a vasodilating beta-blocker, would be more effective than bisoprolol, a beta1- selective beta-blocker in reducing central pulse pressure and thereby LV mass, through the reduction in the magnitude of reflection wave. The aim of the present study was to test this hypothesis in an active controlled, 2-arm parallel group comparison, prospective randomized open blinded end-point (PROBE) design study. At least 100 patients will be enrolled in each group and the follow up duration will be 48 weeks. The primary endpoint is to compare the change in central pulse pressure between the two groups.
Interventions
DRUGcarvedilol
carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP \<140/90 mmHg.
DRUGbisoprolol
bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP \<140/90 mmHg.
Sponsors
Yoshio Matsui
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Never-treated hypertensive subjects, aged 20-80 years (at the time of informed consent), regardless of sex * Clinic systolic BP/diastolic BP \> 140/90 mmHg in a sitting position.
Exclusion criteria
* Beta-blocker contraindications(asthma, COPD…) * Heart rate less than 55 bpm * Subjects treated with nitrates * Grade 3 hypertension (≥180 and/or ≥110 mmHg) * Secondary hypertension or malignant hypertension * History of heart failure, coronary artery disease, and stroke * Arrhythmia * Renal dysfunction (serum creatinine ≥2.0 mg/dl) * Hepatic dysfunction (AST and/or ALT ≥100 IU/l) * A history of or a suspected malignant tumor within 5 years of enrollment * Chronic inflammatory disease * Pregnancy, childbearing potential with inadequate contraception, breast feeding * Inability to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in central pulse pressure (pulse pressure amplification) | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Change in LV mass index Changes in LV diastolic functions (E/Em, left atrium volume) Changes in urinary albumin excretion, B-type natriuretic peptide (BNP), HOMA-IR, and oxidative stress (urinary 8-isoprostane). Change in ambulatory BP | 12 months |
Countries
Japan
Contacts
Primary ContactYoshio Matsui
Outcome results
None listed